Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1292-1296

  Tang, Kai ^a   Jin, Qiang ^a   Yan, Wei ^a   Zhang, Wei ^a   You, Gan ^a   Liu, Yanwei ^a   Jiang, Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma; Methylation; MGMT

Indexed keywords

6 O METHYLGUANINE; DNA METHYLTRANSFERASE; DNA; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CHILD; DNA METHYLATION; DNA SEQUENCE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PYROSEQUENCING; SCHOOL CHILD; ADOLESCENT; BRAIN TUMOR; CHINA; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION; PROMOTER REGION; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; CHINA; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84866297318     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9901-4     Document Type: Article

References (17)

1. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010;67:279-83.
2. Dunn J, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009;101:124-31.
3. Rivera AL, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12:116-21.
4. Nagane M, Kobayashi K, Ohnishi A, Shimizu S, Shiokawa Y. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol. 2007;37:897-906.
5. Kitange GJ, et al. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol. 2009;92:23-31.
6. Zhang W, et al. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. Chin Med J (Engl). 2009; 5(122):1250-4.
7. Nishikawa R. Standard therapy for glioblastoma-a review of where we are. Neurol Med Chir (Tokyo). 2010;50:713-9.
8. Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
9. Blanc JL, et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol. 2004;68:275-83.
10. Brell M, et al. Prognostic significance of O6-methylguanine- DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005;11:5167-74.
11. Rodriguez FJ, et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol. 2008;16:59-65.
12. Franceschi E, Tosoni A, Pozzati E, Brandes AA. Association between response to primary treatments and MGMT status in glioblastoma. Expert Rev Anticancer Ther. 2008;8:1781-6.
13. Hegi ME, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189-99.
14. van den Bent MJ, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009; 27:5881-6.
15. Hassel JC, et al. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer. 2010;103:820-6.
16. Sarkaria JN, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900-8.
17. Everhard S, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol. 2009;11:348-56.